Review: ACE-Is or ARBs reduce adverse CV outcomes regardless of baseline systolic blood pressure

Annals of Internal Medicine

Volumn 157, Issue 2, 2012, Pages

  Singh, Vibhuti ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

EID: 84863890978     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-2-201207170-02008     Document Type: Review

References (2)

1. Fraker TD Jr, Fihn SD, 2002 Chronic Stable Angina Writing Committee; et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50:2264-74.
2. Remme WJ. Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE [Editorial]. Cardiovasc Drugs Ther. 2007;21:405-7.